

# Apple Health PDL Drug Class Motions

# Oncology Agents

---

- ▶ Alkylating Agents - Oral
- ▶ Antimetabolites - Oral
- ▶ Antineoplastics Misc - Oral
- ▶ BCL-2 Inhibitors- Oral
- ▶ Histone Deacetylase Inhibitors – Oral
- ▶ Immunomodulators- Oral
- ▶ Isocitrate Dehydrogenase-1 (IDH1) Inhibitors - Oral
- ▶ Isocitrate Dehydrogenase-2 (IDH2) Inhibitors- Oral
- ▶ Janus Associated Kinase (JAK) Inhibitors – Oral
- ▶ Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral
- ▶ Proteasome Inhibitors – Oral
- ▶ XPO1 Inhibitors - Oral

# Oncology Agents

---

## ▶ Recommendation:

- ▶ All products in the drug class listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Oncology Agents

---

- ▶ **Motion:** I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2<sup>nd</sup>: Lee**

# Immune Modulators: Myelodysplastic Syndromes

---

## ▶ Recommendation:

- ▶ All products in the Immune Modulators: Myelodysplastic Syndromes drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Immune Modulators: Myelodysplastic Syndromes

---

- ▶ **Motion:** I move that all products in the Immune Modulators: Myelodysplastic Syndromes drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Huynh**
- ▶ **2<sup>nd</sup>: Brown**

# Cytokine and CAM Antagonists

---

## ▶ Recommendation:

- ▶ All products in the Cytokine and CAM Antagonists drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All Cytokine and CAM Antagonists require prior authorization to determine medical necessity
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Cytokine and CAM Antagonists

---

- ▶ **Motion:** I move that all products in the Cytokine and CAM Antagonists drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization for medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2<sup>nd</sup>: Schwilke**



# Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS)

---

## ▶ Recommendation:

- ▶ All products in the Hematopoietic Agents: Erythropoiesis-Stimulating Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All Erythropoiesis Stimulating Agents require prior authorization to determine medical necessity
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS)

---

- ▶ **Motion:** I move that all products in the Hematopoietic Agents: Erythropoiesis Stimulating Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization for medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Park**
- ▶ **2<sup>nd</sup>: Huynh**

# Hematopoietic Agents: Granulocyte Colony-Stimulating Factors (G-CSF)

---

## ▶ Recommendation:

- ▶ All products in the Hematopoietic Agents: Granulocyte Colony Stimulating Factors drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All Granulocyte Colony-Stimulating Factors require prior authorization to determine medical necessity
- ▶ All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated or not clinically appropriate.

# Hematopoietic Agents: Granulocyte Colony-Stimulating Factors (G-CSF)

---

- ▶ **Motion:** I move that all products in the Hematopoietic Agents: Granulocyte Colony-Stimulating Factors drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated or not clinically appropriate.
- ▶ **Motion: Lee**
- ▶ **2<sup>nd</sup>: Park**

# Hematopoietic Agents: Sickle Cell Anemia

---

## ▶ Recommendation:

- ▶ All products in the Hematopoietic Agents: Sickle Cell Anemia drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Hematopoietic Agents: Sickle Cell Anemia

---

▶ **Motion:** I move that all products in the Hematopoietic Agents: Sickle Cell Anemia drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion:**

▶ **2<sup>nd</sup>:**